Next Article in Journal
Reply to: Comment on Increased Reliance on Physician Assistants: An Access-Quality Tradeoff?
Previous Article in Journal
Transformative Potential of Artificial Intelligence in Global Health Policy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 11
Issue 1
10.1080/20016689.2023.2230663
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments

by
Andrea Aiello
1,
Elisa Elena Mariano
1,*,
Mariangela Prada
1,
Cristina Teruzzi
2,
Nicoletta Martone
2,
Stefano Capri
3,
Giuseppe Carli
4 and
Sergio Siragusa
5
1
Intexo Società Benefit, Milan, Italy
2
Sobi, Milan, Italy
3
School of Economics and Management, LIUC University, Castellanza, Italy
4
Department of Haematology, “S. Bortolo” Hospital, Vicenza, Italy
5
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMise), University of Palermo, Palermo, Italy
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2023, 11(1), 2230663; https://doi.org/10.1080/20016689.2023.2230663
Submission received: 9 May 2023 / Revised: 31 May 2023 / Accepted: 23 June 2023 / Published: 30 June 2023

Abstract

ABSTRACT Introduction: Primary immune thrombocytopenia is a rare autoimmune disease characterised by a decreased platelet count resulting in an increased risk of bleeding events and even life-threatening haemorrhages. Thrombopoietin receptor agonists (TPO-RAs) are the standard of care second-line therapy for adult patients with chronic immune thrombocytopenia. The first TPO-RAs approved and reimbursed in Italy, eltrombopag and romiplostim, while effective, pose some issues in terms of safety (e.g., hepatotoxicity) or general management (e.g., dietary restrictions). Avatrombopag, an effective and well-tolerated TPO-RA, was recently granted reimbursement. Methods: A 3-year (2023–2025) budget impact analysis (BIA) was conducted to estimate its impact on the Italian National Health Service (NHS). Two scenarios were compared, of which one represents the current situation, without avatrombopag, and the other provides for an increasing market share of avatrombopag (up to 26.6%). Results: BIA shows that the increase in the use of avatrombopag correlates with savings for NHS: in the first year, saving would be €1,300,564, increasing to €2,774,210 in the third year, for a total of €6,083,231 over the 3-year period. The sensitivity analysis confirmed these savings in the scenario with avatrombopag. Conclusions: Based on this BIA, the introduction and reimbursement of avatrombopag is an efficient and advantageous choice for the Italian NHS.
Keywords: avatrombopag; budget impact analysis; cost savings; primary immune thrombocytopenia; Italy avatrombopag; budget impact analysis; cost savings; primary immune thrombocytopenia; Italy

Share and Cite

MDPI and ACS Style

Aiello, A.; Mariano, E.E.; Prada, M.; Teruzzi, C.; Martone, N.; Capri, S.; Carli, G.; Siragusa, S. Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments. J. Mark. Access Health Policy 2023, 11, 2230663. https://doi.org/10.1080/20016689.2023.2230663

AMA Style

Aiello A, Mariano EE, Prada M, Teruzzi C, Martone N, Capri S, Carli G, Siragusa S. Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments. Journal of Market Access & Health Policy. 2023; 11(1):2230663. https://doi.org/10.1080/20016689.2023.2230663

Chicago/Turabian Style

Aiello, Andrea, Elisa Elena Mariano, Mariangela Prada, Cristina Teruzzi, Nicoletta Martone, Stefano Capri, Giuseppe Carli, and Sergio Siragusa. 2023. "Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments" Journal of Market Access & Health Policy 11, no. 1: 2230663. https://doi.org/10.1080/20016689.2023.2230663

APA Style

Aiello, A., Mariano, E. E., Prada, M., Teruzzi, C., Martone, N., Capri, S., Carli, G., & Siragusa, S. (2023). Budget Impact Analysis for Avatrombopag in the Treatment of Chronic Primary Immune Thrombocytopenia in Adult Patients Refractory to Other Treatments. Journal of Market Access & Health Policy, 11(1), 2230663. https://doi.org/10.1080/20016689.2023.2230663

Article Metrics

Back to TopTop